Prøve GULL - Gratis
Mideast escalation may drive correction in overvalued India stocks
Mint Hyderabad
|June 16, 2025
FPIs are staying away due to expensive valuations. Most FPIs are awaiting a correction in India Pratik Gupta CEO & co-head, Kotak Institutional Equities
An escalation of hostilities in the Middle East makes India vulnerable to oil price shocks and could result in a correction in stock prices, which already seem overvalued based on earnings estimates for the current fiscal, according to Pratik Gupta, chief executive officer and co-head of Kotak Institutional Equities.
Gupta said this could cap market upside over the next few months but expects earnings to pick up in the second half of the current fiscal. Foreign portfolio investors acknowledge India's strong macros and resilience of domestic flows, but await a correction to make large fresh investments, he said.
Edited excerpts:
Nifty earnings in FY25 grew in modest single digits, reflected in market valuations correcting from October to March. Our GDP growth is slated at 6.5% and inflation at 3.7% for the current fiscal, per the central bank. That means nominal growth of around 10%. How do you see Nifty and the broader market earnings pan out this fiscal year in this context? Do you expect the correction in markets since October to continue, or is the worst behind us?
We expect net profits of the Nifty 50 Index to grow 12% in FY26 and 15% in FY27, following a modest 6.4% growth in FY25. Diversified financials, metals & mining, oil, gas & consumable fuels and telecom will provide the bulk of the incremental profits for FY26 of the Nifty 50 Index. The sector-wise trends for the broader Kotak coverage universe of almost 300 companies are very similar to the sector-wise trends for the Nifty 50 Index. We estimate that the metals & mining sector will account for 22% and 16% of the incremental profits of FY26 of the Nifty 50 Index and KIE coverage universe, respectively.
Denne historien er fra June 16, 2025-utgaven av Mint Hyderabad.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Mint Hyderabad
Mint Hyderabad
Nvidia, Eli Lilly to invest $1 bn in AI lab
Nvidia Corp. plans to invest $1 billion over five years in a new laboratory with Eli Lilly & Co., aiming to speed up the use of artificial intelligence (AI) in the pharmaceutical industry.
1 min
January 13, 2026
Mint Hyderabad
Shadowfax IPO to open next week
Logistics services provider Shadowfax is set to launch its ₹1,900-crore initial public offering (IPO) next week, targeting a valuation of ₹7,400 crore, people familiar with the matter said on Monday.
1 min
January 13, 2026
Mint Hyderabad
The US climate cop-out should galvanize others
America's withdrawal from the global battle against climate change is a signal for the rest of the world to unite for the greater good. The cause is vital, not the participation of the US
2 mins
January 13, 2026
Mint Hyderabad
Toyota pushes for fuel norm clarity
The government should soon come out with the final notification for the next phase of India’s Corporate Average Fuel Efficiency standards so that the industry can prepare accordingly, according to a senior Toyota Kirloskar Motor executive.
1 min
January 13, 2026
Mint Hyderabad
Food effect lifts Dec CPI inflation
India's retail inflation rose for the second successive month in December, data released by the statistics ministry on Monday showed, driven by a moderation in negative food inflation and an uptick in core inflation.
1 min
January 13, 2026
Mint Hyderabad
Commissions trump advice in wealth management biz
surge on rising affluence, strong economic growth, higher foreign direct investments, and the growth of the startup ecosystem.
2 mins
January 13, 2026
Mint Hyderabad
The Chinese company taking on the world's memory-chip giants
As AI demand drives prices up, CXMT beats Washington's curbs to vie with Micron and South Korean leaders
4 mins
January 13, 2026
Mint Hyderabad
HC lifts ban on Zydus cancer biosimilar till patent expiry
In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.
2 mins
January 13, 2026
Mint Hyderabad
Fix GST on capital goods to revive private investment
India faces a paradox today.
3 mins
January 13, 2026
Mint Hyderabad
Feeling tired? It could be too many messages
The cumulative stress of constant notifications is leaving many emotionally burnt out. Tackling it requires small, sustainable changes
4 mins
January 13, 2026
Listen
Translate
Change font size
